Tech Transfer eNews Blog

U of Liverpool start-up develops vaccine platform targeting bacterial infectious diseases


By Jesse Schwartz
Published: November 16th, 2022

A start-up from the University of Liverpool is commercializing a technology that could significantly alter the incidence of bacterial infectious diseases around the world.

ReNewVax is developing a platform to produce safe, easy-to-manufacture and affordable vaccines for global use. The start-up aims to target some of the most challenging bacterial infections, including pneumonia, meningitis and sepsis.

ReNewVax recently secured nearly £300K in seed funding from Innovate UK, with matching funds from the University of Liverpool’s Enterprise Investment Fund.

“We are very excited to have been awarded seed funding from Innovate UK to support our spin-out venture,” says Aras Kadioglu, professor at the University of Liverpool and co-founder and director of ReNewVax Ltd. “The capital will allow us to complete the pre-clinical studies for our novel pneumococcal vaccine and raise further investment to undertake initial clinical development through Phase I/II studies.”

The start-up anticipates its proprietary vaccine against the disease-causing bacterium pneumococcus will enter early phase clinical trials in 2025.

Anthony Hollander, Pro-Vice-Chancellor for Research and Impact at the University of Liverpool, comments, “This is another example of ground-breaking research developed at the University of Liverpool, and I’m delighted that we have been able to invest match funding in the company.”

Source: Mirage News

Posted under: Tech Transfer e-News